101 results
Page 4 of 6
8-K
EX-99.1
o3xe 6vbnc
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
31de3y8bo0 rqd0tt
5 Nov 20
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:31am
8-K
EX-99.1
gdjtvui3p8v92
4 Aug 20
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:47pm
8-K
EX-99.1
5rs1404wx vh2
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
EX-99.2
du0 iz1khahe
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
kchk f036z
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
g8wns mrk0cytdkjuxd
14 May 20
Other Events
12:00am
8-K
EX-99.1
7gihn6ti0bn3z1dmo
16 Mar 20
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:01am
8-K
EX-1.1
wc6e3vjwy
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
424B5
dek56eax
7 Nov 19
Prospectus supplement for primary offering
4:05pm
424B5
abfq mjyc6p2zm64
6 Nov 19
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.1
0czbnw
4 Nov 19
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
5:10pm
8-K
EX-99.2
cgmqczu
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am
8-K
EX-99.1
5jv0zs2qq y43izh9t
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am